Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2605502 | 0.83 | HTT (0.38) | PIK3CGIDH1 | |
| SCHEMBL10147793 | 0.79 | PIK3CG (0.34) | PIK3CGIDH1 | |
| SCHEMBL9449998 | 0.79 | PIK3CG (0.34) | PIK3CGIDH1 | |
| SCHEMBL21180509 | 0.77 | PIK3CG (0.35) | PIK3CGIDH1 | |
| SCHEMBL14213299 | 0.76 | PIK3CG (0.33) | PIK3CGIDH1 | |
| SCHEMBL24704040 | 0.75 | PIK3CG (0.32) | PIK3CGIDH1 | |
| SCHEMBL20049229 | 0.75 | PIK3CG (0.32) | PIK3CGIDH1 | |
| SCHEMBL23490727 | 0.73 | PIK3CG (0.33) | PIK3CGIDH1 | |
| SCHEMBL13187109 | 0.71 | ACHE (0.31) | — | |
| SCHEMBL9963349 | 0.71 | ACHE (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10683291-B2 | Heterocyclic compounds for the treatment of disease | OPPILAN PHARMA LTD. (GB) | 2020-06-16 | — | — | US | disclosed |
| US-20190292173-A1 | COMPOUNDS CONTAINING BENZO[D][1,3]OXATHIOLE, BENZO[D][1,3]OXATHIOLE 3-OXIDE OR BENZO[D][1,3]OXATHIOLE 3,3-DIOXIDE AND METHODS/USES THEREOF AS AGONISTS OF G PROTEIN-COUPLED RECEPTOR 119 | PRAMANA PHARMACEUTICALS INC. (CA) | 2019-09-26 | — | — | US | disclosed |
| US-20190241556-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | OPPILAN PHARMA LTD. (GB) | 2019-08-08 | — | — | US | disclosed |
| WO-2018067704-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292173-A1 | COMPOUNDS CONTAINING BENZO[D][1,3]OXATHIOLE, BENZO[D][1,3]OXATHIOLE 3-OXIDE OR BENZO[D][1,3]OXATHIOLE 3,3-DIOXIDE AND METHODS/USES THEREOF AS AGONISTS OF G PROTEIN-COUPLED RECEPTOR 119 | GPR119, GPR3, GPR39 | PIK3CG 2177/4885IDH1 3982/4885 |
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | PIK3CG 3417/4885IDH1 3928/4885 |
| US-20190241556-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, FH, TPMT | PIK3CG 4011/4885IDH1 26/4885 |
| US-10683291-B2 | Heterocyclic compounds for the treatment of disease | VHL, FH, TPMT | PIK3CG 4011/4885IDH1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.